Exelixis
EXEL
#1609
Rank
S$13.68 B
Marketcap
$48.90
Share price
-0.97%
Change (1 day)
53.15%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.38

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.38. In 2022 the company made an earnings per share (EPS) of $0.76 a decrease over its 2021 EPS that were of $0.99.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.38-49.7%
2022$0.76-22.97%
2021$0.99100%
2020$0.49-65.09%
2019$1.41-53.91%
2018$3.07333.96%
2017$0.71-260.61%
2016-$0.44-58.75%
2015-$1.07-42.45%
2014-$1.855.3%
2013-$1.7643.48%
2012-$1.23-264.29%
2011$0.75-165.88%
2010-$1.13-32.54%
2009-$1.68-17.65%
2008-$2.0475.86%
2007-$1.16-25.64%
2006-$1.568.33%
2005-$1.44-42.86%
2004-$2.5230.34%
2003-$1.93-5.23%
2002-$2.04-0.65%
2001-$2.05-51.88%
2000-$4.27

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$4.67 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$4.24 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$2.43 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.29 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$18.86 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$18.78 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.48 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$13.33-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.12-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA